Data on CSF dementia markers (14-3-3, tau, phosphorylated tau and amyloid-β1–42) were evaluated in a total of 3034 patients (28.3% of the total group) with a neurodegenerative disease diagnosis. Here, MAPT is linked to neurodegenerative disease.